Evidence of clinical benefit of WHO essential anticancer medicines for children, 2011-2021.

ABSTRACT:

Background

Access to essential cancer medicines is a key determinant of childhood cancer survival. WHO published the Model List of Essential Medicine for Children (EMLc) and updated it every two years since 2007 to promote better access to medicines for children. This study aimed to assess whether the inclusion of essential anticancer medicines for respective indications for children was based on evidence of significant clinical benefit between 2011 and 2021.

Methods

We identified all anticancer medicine indications added to the WHO EMLc Section 8 since 2011 and extracted evidence of benefit documented in the corresponding technical reports. Evidence in children was defined as evidence that included participants under 12, and graded into five levels, according to the Oxford

SUBMITTER: Bai L 

PROVIDER: S-EPMC10130597 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature